Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-09 · 1879 (5) · 189174
DOI: 10.1016/j.bbcan.2024.189174 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-09. Verfasst von Yang Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The therapeutic landscape for hormone receptor-positive (HR+) breast carcinoma has undergone a significant transformation with the advent of cyclin-dependent kinase (CDK)4/6 inhibitors, particularly in combination with endocrine therapy as the primary regimen. However, the evolution of resistance mechanisms in response to CDK4/6 inhibitors in HR+ metastatic breast cancer presents substantial challenges in managing the disease. This review explores the diverse genomic landscape underlying resistance, including disturbances in the cell cycle, deviations in oncogenic signaling pathways, deficiencies in DNA damage response (DDR) mechanisms, and changes in the tumor microenvironment (TME). Additionally, it discusses potential strategies to surmount resistance, including advancements in endocrine therapy, targeted inhibition of cell cycle components, suppression of AKT/mTOR activation, exploration of the FGFR pathway, utilization of antibody-drug conjugates (ADCs), and integration of immune checkpoint inhibitors (ICIs) with endocrine therapy and CDK4/6 inhibitors, providing pathways for enhancing patient outcomes amidst treatment challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.
- Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, China. Electronic address: nspdoctor@sr.gxmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, Y., Zhang, Z., Li, D., Huang, R., & Ning, S. (2024). Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(5), 189174. https://doi.org/10.1016/j.bbcan.2024.189174
Vancouver
Zheng Y, Zhang Z, Li D, Huang R, Ning S. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(5):189174. doi:10.1016/j.bbcan.2024.189174
BibTeX
@article{Zheng2024,
author = {Zheng, Yang and Zhang, Zeyuan and Li, Dan and Huang, Rong and Ning, Shipeng},
title = {Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {5},
pages = {189174},
doi = {10.1016/j.bbcan.2024.189174}
}
EUVIMED